FAF
NBIX icon

Fjarde Ap-fonden’s Neurocrine Biosciences NBIX Stock Holding History

Fjarde Ap-fonden’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
76,623
+12,400
+19% +$1.84M 0.06% 262
2026
Q1 		$8.46M Buy
64,223
+29,000
+82% +$3.85M 0.05% 314
2025
Q4 		$5M Sell
35,223
-2,000
-5% -$290K 0.04% 337
2025
Q3 		$5.22M Sell
37,223
-21,900
-37% -$2.97M 0.05% 319
2025
Q2 		$7.43M Sell
59,123
-8,500
-13% -$975K 0.07% 264
2025
Q1 		$7.48M Buy
67,623
+12,000
+22% +$1.52M 0.09% 214
2024
Q4 		$7.59M Buy
55,623
+2,300
+4% +$284K 0.08% 243
2024
Q3 		$6.14M Buy
+53,323
New +$7.31M 0.06% 301
2024
Q1 		$5.8M Buy
42,023
+3,500
+9% +$478K 0.06% 305
2023
Q4 		$5.08M Sell
38,523
-6,177
-14% -$711K 0.06% 322
2023
Q3 		$5.03M Buy
44,700
+7,800
+21% +$821K 0.07% 310
2023
Q2 		$3.48M Buy
36,900
+11,000
+42% +$1.07M 0.04% 407
2023
Q1 		$2.62M Buy
25,900
+4,100
+19% +$427K 0.04% 427
2022
Q4 		$2.6M Sell
21,800
-5,300
-20% -$621K 0.04% 432
2022
Q3 		$2.64M Hold
27,100
– – 0.03% 467
2022
Q2 		$2.64M Sell
27,100
-1,200
-4% -$111K 0.03% 467
2022
Q1 		$2.65M Sell
28,300
-7,600
-21% -$644K 0.03% 512
2021
Q4 		$3.06M Buy
35,900
+1,600
+5% +$147K 0.03% 500
2021
Q3 		$3.29M Sell
34,300
-2,800
-8% -$264K 0.03% 499
2021
Q2 		$3.61M Buy
37,100
+2,100
+6% +$201K 0.03% 488
2021
Q1 		$3.4M Buy
35,000
+800
+2% +$83.9K 0.03% 488
2020
Q4 		$3.28M Buy
34,200
+3,000
+10% +$290K 0.03% 487
2020
Q3 		$3M Buy
31,200
+2,700
+9% +$312K 0.03% 475
2020
Q2 		$3.48M Sell
28,500
-700
-2% -$77.4K 0.04% 410
2020
Q1 		$2.53M Sell
29,200
-500
-2% -$48.9K 0.04% 429
2019
Q4 		$3.19M Buy
+29,700
New +$3.11M 0.04% 477

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fjarde Ap-fonden's NBIX Position: Q2 2026 in Review

Fjarde Ap-fonden increased its Neurocrine Biosciences (NBIX) stake by 19% in Q2 2026, buying an estimated $1.84M and bringing the position to 76,623 shares worth $12.9M. The position accounts for 0.06% of the portfolio, ranked #262.

Fjarde Ap-fonden first reported a position in NBIX in Q4 2019 and has held it in 26 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Fjarde Ap-fonden held 76,623 shares of Neurocrine Biosciences worth $12.9M as of Q2 2026.
  • Fjarde Ap-fonden bought 12,400 Neurocrine Biosciences shares in Q2 2026, an estimated $1.84M.
  • Neurocrine Biosciences made up 0.06% of Fjarde Ap-fonden's portfolio in Q2 2026, its #262 holding.
  • Fjarde Ap-fonden first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 26 quarters since.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.